RePORT International Resources

This WHO training kit helps manufacturers and regulators, especially in low- and middle-income countries, learn how to produce safe, effective, and high-quality vaccines, medicines, and diagnostic tests. It compiles expert-reviewed Q&As from the “Week of Quality” training on quality standards, regulatory compliance, and product development, serving as a reference for strengthening local production.

The Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment is a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development on novel regimens for TB treatment. It outlines 21 key messages, explains why they are important, and what approaches can increase the chances of research leading to strong WHO recommendations. The key messages cover areas such as trial design, selection criteria, outcome choice, sample size, analytic and economic considerations, and how to Investigate the impact of an intervention on health equity, acceptability, and feasibility. The evidence available to WHO for use in guideline development has often presented challenges that have limited the strength of recommendations and their applicability to certain population groups or have meant that the evidence is not suitable for policy development. The reasons for these challenges are addressable but are not always well understood by all stakeholders. The guidance provided in the GEG document should allow those who aim to influence policy to design trials and other studies in a way that maximizes the potential to do so.

In 2024, the WHO Global Programme on Tuberculosis & Lung Health led a consensus building process to advance the earlier and optimal inclusion of pregnant women in TB research. The process is aligned with broader global developments to transform clinical trial practices, including addressing the needs of underrepresented populations. This consensus statement summarizes the consensus process, which included five thematic working groups (covering preclinical TB research, TB therapeutics research, TB vaccine research, maternal TB surveillance systems and advocacy), evidence reviews to address gaps in data and knowledge and a consensus meeting in February 2025. The approaches to earlier and optimal inclusion arising from the consensus process include crosscutting actions as well as approaches specific to each working group theme.

The WHO TB Patient Cost Survey resources include a standardized household questionnaire (2025 version) for collecting data on the economic impact of TB, along with companion STATA datasets and code to support data entry, management, and analysis. These tools are designed to promote consistent methodology and facilitate cross-country comparisons in TB research and program evaluation.

The WHO TB Patient Cost Survey resources include a standardized household questionnaire (2025 version) for collecting data on the economic impact of TB, along with companion STATA datasets and code to support data entry, management, and analysis. These tools are designed to promote consistent methodology and facilitate cross-country comparisons in TB research and program evaluation.

The new WHO TPPs for TB screening tests were developed after an extensive consultation of a large cross section of constituencies. They provide manufacturers and other stakeholders in research and development with the latest product- and technology-agnostic guidance that encompass all possible approaches used for TB screening.